Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07188779 · ClinicalTrials.gov registry record · Phase 2
Impact of RADA16 Use on Outcomes Following Tonsillectomy in Children
A Phase 2 study, sponsored by Rutgers, The State University of New Jersey.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 134
- Enrollment target
NCT07188779 is a Phase 2 study that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 134 participants.
The verdict
NCT07188779, a Phase 2 study, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 134 participants
- Enrollment target
Study Summary
The purpose of the research is to determine if RADA16 (also known as PuraStat®, PuraGel®, or PuraSinus®) improves patient outcomes following pediatric tonsillectomy procedures. Researchers will compare application of device RADA16 to application of no device to see if RADA16 works to treat post tonsillectomy hemorrhage.Participants will: Undergo tonsillectomy procedure. Receive and fill out a survey sent via email every 2 days following their procedure for 15 days, plus an additional survey on day 30, and track their symptoms.
Interventions
- DEVICE RADA16 hydrogel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2027-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07188779
The ClinicalTrials.gov registry entry for NCT07188779 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RADA16 hydrogel is the first listed.
NCT07188779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07188779 about?
NCT07188779 is a clinical study titled "Impact of RADA16 Use on Outcomes Following Tonsillectomy in Children". The purpose of the research is to determine if RADA16 (also known as PuraStat®, PuraGel®, or PuraSinus®) improves patient outcomes following pediatric tonsillectomy procedures. Researchers will compare application of device RADA16 to application of no device to see if RADA16 works to treat post tons...
What is the current status of trial NCT07188779?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 134 participants. The study started on 2026-07-01. Estimated completion is 2027-12-01.
What interventions are being tested in trial NCT07188779?
The interventions under investigation include: RADA16 hydrogel (DEVICE).
Who is sponsoring clinical trial NCT07188779?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.